## MRK: Merck & Company, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($96.01)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Merck (NYSE: MRK) gets FDA Fast Track for MK-2214, shares human Alzheimer’s data at CTAD**
- Source: Stock Titan | 20251201T064500 | Bullish | Relevance: 99%
- Merck announced that its Alzheimer's disease candidate, MK-2214, received FDA Fast Track Designation. The company will present first-in-human data for both MK-2214 and MK-1167 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference. These presentations will include Phase 1 study results and design information for ongoing Phase 2 trials, highlighting Merck's continued efforts in neuroscience to address Alzheimer's disease.

**2. Hamel Associates Inc. Acquires 7,316 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251130T102501 | Bullish | Relevance: 99%
- Hamel Associates Inc. increased its stake in Merck & Co., Inc. by 8.5% in the second quarter, bringing its total holdings to 93,287 shares valued at $7.39 million. Other institutional investors like Vanguard Group Inc., Wellington Management Group LLP, and Charles Schwab Investment Management Inc. also adjusted their positions. The article includes recent analyst ratings, insider trading activity, and a financial overview of Merck & Co., Inc., highlighting its recent dividend increase and earnings performance.

**3. Merck seeks up to US$8 bil in US bond sale tied to Cidara deal — Bloomberg**
- Source: Yahoo Finance Singapore | 20251201T073200 | Somewhat-Bullish | Relevance: 99%
- Merck & Co Inc is planning a corporate bond sale of up to US$8 billion to help fund its proposed acquisition of Cidara Therapeutics Inc. The bond sale will include eight parts with maturities ranging from three to 40 years, with a portion of the proceeds also earmarked for debt repayment. This offering contributes to a record year for global bond issuance, taking advantage of strong investor appetite.

**4. Scotia Capital Inc. Trims Stake in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251129T114633 | Somewhat-Bullish | Relevance: 99%
- Scotia Capital Inc. reduced its stake in Merck & Co., Inc. by 14.9% during the second quarter, selling 42,380 shares and now holding 241,686 shares valued at approximately $19.13 million. Despite this reduction, several other institutional investors like Vanguard Group Inc., Wellington Management Group LLP, Charles Schwab Investment Management Inc., DLD Asset Management LP, and Franklin Resources Inc. increased their positions in MRK. The article also provides details on analyst ratings, stock performance, recent earnings, dividend increases, and insider trading activity for Merck.

**5. Merck Showcases Data For Alzheimer's Disease Candidates Mk-2214 And Mk-1167 At Ctad 2025**
- Source: TradingView | 20251201T130635 | Somewhat-Bullish | Relevance: 99%
- Merck & Co Inc (MRK) announced that it will showcase data for its Alzheimer's disease candidates, MK-2214 and MK-1167, at the Clinical Trials on Alzheimer's Disease (CTAD) conference in 2025. This news highlights Merck's ongoing commitment to developing treatments for Alzheimer's.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $120 | $105 | +14% |
| 2025-12-02 | Goldman Sachs | $120 | $92 | +30% |
| 2025-11-24 | Wells Fargo | $125 | $90 | +39% |
| 2025-11-18 | Deutsche Bank | $111 | $110 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Outperform |
| 2025-12-02 | Goldman Sachs | main | Buy |
| 2025-11-24 | Wells Fargo | up | Overweight |
| 2025-11-18 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.09M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 4 raises (avg +21%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.80 indicates undervaluation relative to growth. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (4 raises, avg +21%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $243.8B |
| Beta | 0.30 |
| 52W Range | $73.31 - $105.84 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.80 |
| Forward P/E | 11.9 |
| Current P/E | 11.4 |
| YoY Growth | -4.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 5.6% to 0.2% (-5.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 (-2.1%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.07), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.25% (CS: 65) | Neutral |
| RSI_14 | 68.9 | Neutral |
| MACD Histogram | 1.07 | Bullish |
| vs SMA20 | 1.088x | Above |
| vs SMA50 | 1.149x | Above |
| vs SMA200 | 1.205x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.83
- **Stop Loss:** $96.01 (5.7% risk)
- **Target:** $107.65 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 128
- **Position Value:** $13,034.24
- **Portfolio %:** 13.03%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*